Skip to main content
Show — Main navigation
Hide — Main navigation
Home
About
The Chair
Inquiry Team
Expert Groups
Inquiry Intermediaries
Core Participants
Legal Representatives
Financial Reports
Approach
Terms of reference
List of Issues
Statements of approach
Inquiry Principles
News
News
Newsletter Archive
Reports
The Inquiry Report
Additional Compensation report
First Interim Report
Second Interim Report
Compensation Framework Study
Evidence
Evidence
Hearings Archive
Compensation
Support
NHS Psychological Support
Confidential Psychological Support
Support Groups
Infected Blood Support Schemes
Treatment and aftercare
Medical Evidence
Expenses Guidance
Contact us
Search
Accessibility Tool
Zoom in
Zoom out
Reset
Contrast
Accessibility tool
Listen
Get in touch
Quick Exit
Subscribe to Search results
Search
Sort your search results
Relevance
Title
Changed
Similar concerns regarding use of Factor VIII concentrates and purchase of commercial products were raised at the meeting of the Lothian Health Board Area Executive Group.
Published on:
30 September, 2024
Dr Boulton continued to express concerns that Dr Ludlam's home therapy programme was using a large proportion of the allocation from PFC and that he may need to buy commercial Factor VIII if the usage pattern continued.
Published on:
30 September, 2024
Dr Boulton stated that Dr Ludlam was beginning to use less PFC material in favour of cryoprecipitate and that this was an encouraging trend. Edinburgh also sourced Factor VIII from Inverness and Glasgow.
Published on:
30 September, 2024
Dr Ludlam felt that he was not getting the supply of PFC material that had been agreed.
Published on:
30 September, 2024
At Edinburgh Haemophilia Centre, there was a reduction in the use of cryoprecipitate and an increase in the use of NHS concentrate, with both Factorate and Koate being used in larger quantities than before.
Published on:
30 September, 2024
At Edinburgh Haemophilia Centre, there was a further reduction in the use of cryoprecipitate and an increase in NHS concentrate; some commercial concentrate was also used.
Published on:
30 September, 2024
Professor Ludlam described his perception of non-A non-B Hepatitis as being that until the late 1980s it was seen as a "mild non-progressive condition, the first serious study on liver biopsy having been undertaken in 1985."
Published on:
30 September, 2024
The treating paediatricians of the San Francisco baby published a report, showing that the only possible alternative cause might be a primary immunodeficiency disorder and setting out why the clinical and laboratory findings suggested that a transmissible infectious agent had resulted in AIDS.
Published on:
30 September, 2024
Professor Ludlam realised that factor concentrates not only gave rise to a potential risk of non-A, non-B infection and a real risk of HIV infection, but could also give rise to a deterioration in the immune system.
Published on:
30 September, 2024
Professor Ludlam thought the link between HIV and a deterioration in the immune system had been recognised by the virologist Professor Tedder: that AIDS could occur as a result of the side effects of impurities in the concentrates.
Published on:
30 September, 2024
Professor Ludlam received the first results from an AIDS study of his and was surprised, perplexed, and puzzled as he had expected no problem with those who had been on Scottish PFC concentrate.
Published on:
30 September, 2024
At the Edinburgh Royal Infirmary, tests were undertaken using stored samples - where people were unaware their sera had been stored - both in relation to HIV testing and to Hepatitis B testing with second-generation tests.
Published on:
30 September, 2024
A meeting of SNBTS and haemophilia directors recorded Professor Ludlam saying cryoprecipitate was preferable for treating children because of AIDS, with Dr Hann concurring, but that a policy seemed to be emerging to use less cryoprecipitate for haemophilia A patients.
Published on:
30 September, 2024
Dr Tedder gave evidence that Professor Ludlam had a "clinical suspicion" which was why he had sent stored samples to Dr Tedder for testing in autumn 1984.
Published on:
30 September, 2024
By 26 October 1984, Professor Ludlam had learned that six patients with haemophilia had developed antibody to HTLV-3; by 2 November he had received further test results relating to sixteen patients.
Published on:
30 September, 2024
Professor Ludlam wrote to a colleague at the Royal Infirmary that "It has recently become apparent to me that some of our patients with haemophilia have antibody to HTLV III virus."
Published on:
30 September, 2024
Dr Craske explained that he was awaiting the results of biopsy studies being undertaken in Sheffield and at the Royal Free, and it was recorded that there were other studies underway or anticipated in Oxford and Manchester.
Published on:
27 September, 2024
UK Government announces interim compensation payments following Inquiry recommendation
Published on:
17 August, 2022
Professor Bloom stated it was "a matter for the individual Directors to decide." He referred to the minutes of the fifth meeting of Haemophilia Reference Centre Directors (January 1978) where it was agreed factor VIII concentrates were preferred for home therapy to cryoprecipitate.
Published on:
27 September, 2024
Professor Savidge stated "I think the majority of responsible physicians knew by the end of the 70s that large donor pool concentrates, whether it be for Factor 8 or Factor 9 were the cause of non-A/non-B hepatitis".
Published on:
27 September, 2024
Pagination
First page
First
Previous page
Previous
…
Page
2332
Page
2333
Page
2334
Page
2335
Current page
2336
Page
2337
Page
2338
Page
2339
Page
2340
…
Next page
Next
Last page
Last